PROCEPT BioRobotics (PRCT) Net Cash Flow (2020 - 2026)

PROCEPT BioRobotics (PRCT) has 7 years of Net Cash Flow data on file, last reported at -$40.8 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 133.01% year-over-year to -$40.8 million in Q1 2026; TTM through Mar 2026 was -$70.4 million, a 177.73% decrease from a year earlier, with the FY2025 full-year figure at -$47.1 million, down 161.63% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$40.8 million, down from -$7.7 million in the prior quarter.
• Over the last five years, Net Cash Flow for PRCT reached as high as $137.4 million in Q3 2023 and fell as low as -$40.9 million in Q1 2023.
• Historically, Net Cash Flow has averaged -$3.3 million across 5 years, with a median of -$17.3 million in 2024.
• On a YoY basis, Net Cash Flow climbed as much as 767.36% in 2023 and fell as far as 140.58% in 2023.
• Year by year, Net Cash Flow stood at -$27.4 million in 2022, then declined by 12.0% to -$30.6 million in 2023, then surged by 546.98% to $137.0 million in 2024, then plunged by 105.65% to -$7.7 million in 2025, then sank by 427.58% to -$40.8 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$40.8 million in Q1 2026, -$7.7 million in Q4 2025, and -$8.4 million in Q3 2025.